The Star-Ledger sat down with Tom Koestler, the research chief for Schering-Plough, to review its progress developing new therapies and integrating the R&D section of Organon. Koestler and CEO Fred Hassan (photo [1]) have been lauded for their work turning the company around. Analysts now generally give the company top marks for creating a promising pipeline. And while some have questioned the $14.4 billion price tag for Organon [2], there are five other late-stage products offering some major earnings potential. The combined R&D operations includes 7,000 employees working in 42 sites. It's all built around the working philosophy of "customer-focused product flow," where reps from research, manufacturing and marketing all have a hand in guiding the research. "That's kind of like a religion we follow at Schering-Plough," Koestler told the Star-Ledger. "You can't just rely on the scientists to develop a compound."
- check out the report [3] from the Star-Ledger
ALSO: Schering-Plough says the FDA has accepted its NDA for asenapine, a tablet for schizophrenia and bipolar disorder. Release [4]
Related Articles:
Schering-Plough CEO applauded for turnaround. Report [5]
Hassan bullish on Schering-Plough. Report [6]
Schering-Plough's turnaround plan may include buyouts. Report [7]
Links:
[1] http://www.fiercebiotech.com/pages/schering-plough-ceo-fred-hassan
[2] http://www.fiercebiotech.com/story/schering-plough-pays-14.4b-for-organon/2007-03-12
[3] http://www.nj.com/business/ledger/index.ssf?/base/business-1/1195969681248600.xml&coll=1&thispage=2
[4] http://www.fiercebiotech.com/press-releases/press-release-schering-plough-announces-asenapine-nda-accepted-filing-u-s-fda
[5] http://www.fiercebiotech.com/story/schering-plough-ceo-applauded-for-turnaround/2007-05-04
[6] http://www.fiercebiotech.com/story/spotlight-hassan-bullish-on-schering-plough/2007-01-30
[7] http://www.fiercebiotech.com/story/schering-plough-s-turnaround-plan-may-include-buyouts/2006-08-02